Clinical Trials Logo

Penile Induration clinical trials

View clinical trials related to Penile Induration.

Filter by:

NCT ID: NCT05147779 Recruiting - Clinical trials for Erectile Dysfunction

Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells for Peyronie's Disease, ED, and Interstitial Cystitis

Start date: September 12, 2021
Phase: Phase 1
Study type: Interventional

This trial will study the safety and efficacy of intravenous and intracavernosal or interstitial delivery of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Peyronie's disease, erectile dysfunction , and Interstitial Cystitis

NCT ID: NCT05108558 Recruiting - Peyronie's Disease Clinical Trials

Efficacy of a Novel CCH Protocol for PD Among Prior Non-responders

Start date: September 20, 2021
Phase: Phase 4
Study type: Interventional

Compare key clinical outcomes between controls and men treated with a novel CCH administration protocol among men previously unresponsive to CCH administration.

NCT ID: NCT04821115 Recruiting - Peyronie Disease Clinical Trials

Safety and Efficacy of Low-intensity Shockwave Therapy for Peyronie's Disease

ONDELA
Start date: April 6, 2021
Phase: N/A
Study type: Interventional

Investigation of the effect of Low-intensity extracorporeal shockwave therapy (ESWT) for Peyronie's disease (PD) via a single blind, sham-controlled, randomized clinical trial. Investigators will not be blinded to group assignments, but penile curvature will be assessed from coded patient pictures by a blinded assessor.

NCT ID: NCT04786106 Active, not recruiting - Peyronie's Disease Clinical Trials

Investigation of Surgery, Collagenase, and Restorex for the Improvement of Peyronie's

iSCRIP
Start date: December 30, 2020
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare key clinical outcomes of collagenase clostridium histolyticum injections versus surgery for the management of Peyronie's Disease.

NCT ID: NCT04771442 Active, not recruiting - Penile Diseases Clinical Trials

Stem Cell Treatment of Peyronie´s Disease.

Start date: September 9, 2022
Phase: Phase 1
Study type: Interventional

Purpose of the project is to investigate if a single injection of autologous stromal vascular fraction into and around plaque is a safe and suitable treatment. Twentythree men > 18 years with Peyronie´s Disease in the chronic phase will be recruited. The operative same-day procedure will be performed in general anaesthesia by a plastic surgeon. Before the patient wake, local anaesthesia is put around the penis. Processed stem cells are injected into the plaque/fibrosis subcutaneously. There will be a follow up at 1, 3, 6, 12 months. It is a pilot study with no randomisation. The group will be compared to a historical control group.

NCT ID: NCT04512287 Recruiting - Clinical trials for Sexual Dysfunction, Physiological

PRP for Treatment of Peyronie's Disease

Start date: March 29, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to learn about the effects of Platelet-Rich Plasma (PRP) injection in men with Peyronie's Disease (PyD).

NCT ID: NCT04370652 Completed - Peyronie Disease Clinical Trials

Medical Treatment of Peyronie's Disease With Collagenase Clostridium Histolyticum

Start date: January 1, 2015
Phase:
Study type: Observational

Peyronie's disease is the appearance of a fibrosis plaque on the albuginea of the corpora cavernosa, which produces mechanical traction at the time of erection, inducing a deformation/curvature of the erect penis. The physiopathology is largely unknown. There is a significant sexual and psychological impact on patients. Historically, the only possible treatment was surgical. The only drug treatment that was FDA approved for this disease was Collagenase from Clostridium Histolyticum marketed under the name Xiapex® until 31/12/2019 by Sobi laboratory. Marketing was stopped on that date for economic reasons and restricted to the US market only. The investigators propose a retrospective evaluation of the largest French monocentric series of this treatment from the perspective of the sexual and psychological evaluation of patients.

NCT ID: NCT04326465 Completed - Peyronies Disease Clinical Trials

Fractionated Carbon Dioxide Laser Therapy for Treatment of Peyronie's Disease

Start date: May 1, 2021
Phase: N/A
Study type: Interventional

This is a pilot study that evaluates the use of Fractional Carbon Dioxide Laser Therapy in the treatment of Peyronie's Disease. Study participants will be assigned to receive Fractional Carbon Dioxide Laser Therapy at 10-15% laser density coverage.

NCT ID: NCT04052217 Completed - Peyronie Disease Clinical Trials

Does Size Matter: A Single Case Experimental Design of Limiting the Depth of Penetration During Intercourse

Start date: March 1, 2017
Phase: N/A
Study type: Interventional

Our hypothesis is that reducing the length of the penis does not lead to loss of sexual satisfaction or emotional closeness in the female partner. This will be investigated by a single case experimental design in 12 couples.

NCT ID: NCT03815331 Completed - Clinical trials for Peyronie's Disease (PD)

Xiaflex® Plus Testosterone Treatment Pilot Study Protocol

Start date: January 14, 2019
Phase: Phase 4
Study type: Interventional

In this open-label, six-month, pilot study of men with Peyronie's disease there will be one subject group consisting of 20 subjects. All subjects will receive Xiaflex® plus testosterone (T) treatment (Aveed®). Males included in the study must be 18-70 years old; have a history of PD for more than six months; and have at two serum total testosterone level less than 350 ng/dL within 30 days prior to enrollment. The primary objective of this pilot study is to determine whether testosterone therapy offers increased efficacy of Xiaflex® (collagenase clostridium histolyticum) in subjects undergoing treatment for Peyronie's disease. Endpoints will include reduction in degree of curvature and response to the PDQ questionnaire. Secondary objectives will be to assess men for change in plaque size, quality of life parameters, and sexual function. Data collected from this pilot study will be analyzed and compared to historical data regarding treatment for PD using Xiaflex® only. This pilot study will establish preliminary evidence needed to continue more in-depth research regarding Xiaflex® with T therapy and serve as a means to evaluate feasibility of a full-scale study.